There are two ways to harm a patient on long-term opioids. The first is well documented and widely discussed: leave someone on an escalating dose indefinitely and the medication stops working, then starts working against them. The second gets far less attention, and we see it constantly. Take that same patient off abruptly, on a schedule set by a policy rather than by their physiology, and you have not protected them. You have simply chosen a different injury.
Both are failures of the same thinking, which is that the dose is the whole clinical question.
Desensitization is receptor biology, not weakness
Start with the part that is not in dispute. Opioid desensitization is a receptor biologic fact. Continuous exposure to an opioid changes the receptor itself, and the change is mechanical rather than moral. The receptor needs to cycle, and continuous occupancy prevents that cycling. The result is escalation: the same dose produces less relief, so the dose rises, so the receptor is occupied even more continuously.
Past a certain point this stops being a story about diminishing returns and becomes a story about amplification, where the medication is contributing to the pain it was prescribed to treat. We have written about the mechanism in detail in why long-acting opioids can make pain worse and about how to tell that apart from disease progression in is your pain medication making your pain worse.
This is the reason we say an opioid is a bridge, and not a bridge you can live on. Bridges are built to carry you across something. They are not built to be stood on indefinitely, and the structure is not designed for that load.
The opposite error is also harm
None of that argues for pulling the bridge out from under someone mid-crossing.
Regulatory pressure has made many physicians hesitant, and hesitation has a clinical cost that rarely gets counted. A patient tapered abruptly, or discharged from a practice for being on opioids at all, does not become a patient without pain. They become a patient with the same pain, no plan, and often withdrawal on top of it. Some of them go looking for a prescriber. Some of them stop looking for care entirely. Neither outcome is safety, and neither shows up in the metric that made the taper look successful.
Older adults and patients with cancer pain sit at the sharp end of this. Constant, unaddressed pain is not a neutral state. It degrades sleep, function, cardiovascular health and mood, and in the patients least able to absorb that, it can shorten life.
“First, do no harm” was never a mandate to do nothing
The directive gets quoted as though inaction were the safe default. It is not, and it never was.
Almost every meaningful medical intervention carries some risk. Contrast imaging carries risk. Surgery carries risk. Anesthesia, which is the specialty this practice grew out of, carries risk in every case. If “do no harm” meant “accept no risk,” there would be no interventional medicine at all, and physicians would be limited to sympathy.
The ethical framework that actually applies here is the doctrine of double effect, which holds that an intervention carrying some foreseeable harm can still be justified when it is undertaken for a proportionate good. The obligation it creates is not avoidance. It is honest accounting: weigh both sides, choose deliberately, and keep measuring.
That obligation runs in both directions. A physician who prescribes without a plan has failed it. So has a physician who tapers without one.
What an abrupt taper actually does
Stopping or sharply reducing a long-term opioid does not simply subtract the medication. It removes a suppressant from a nervous system that has adapted around its presence.
- Withdrawal, which is physiologically miserable and, in medically fragile patients, genuinely dangerous
- Rebound pain that is worse than the pain the patient had before the taper began, because the adapted system is now unopposed
- Loss of function at exactly the moment the patient needs to be able to participate in rehabilitation
- Loss of the therapeutic relationship, which is the thing most likely to keep that patient safe over the next year
A taper that produces those outcomes has not reduced risk. It has moved risk somewhere it will not be measured.
What replacing the bridge looks like
The reason we can reduce doses at this practice is not discipline or willpower. It is that something takes over the work the medication was doing.
That is the entire clinical purpose of interventional pain management. When an image-guided procedure identifies and treats the structure actually generating the pain, the medication has less to do, and the dose can come down because it is genuinely less necessary rather than because a calendar said so. Metabolic and inflammatory drivers get addressed in parallel, since the terrain determines how much pain a given structure produces.
In practice that means the dose falls as the terrain is rebuilt, reviewed in person, with the timeline able to move when the patient’s physiology says it should. Opioid tapering: medication is a bridge, not a destination describes how that is run.
One thing this is not: an argument for starting or escalating opioid therapy. We do not accept patients seeking opioids as the treatment. The argument here is narrower and, we think, harder to dismiss. Patients already on long-term opioids deserve an exit that is built before the bridge is removed.
Frequently asked questions
Does this mean you will continue my current opioid prescription?
Not as a treatment plan on its own. We take over care with the goal of reducing the dose safely while interventional procedures address what is generating the pain. If you are looking for a practice to maintain or increase a dose indefinitely, we are not that practice.
Will I go into withdrawal?
Avoiding that is the point of doing it this way. A taper is paced to your physiology and reviewed in person, and the timeline moves when it needs to. Withdrawal is a sign the taper is being run wrong, not a necessary stage of it.
Why does my dose keep needing to go up?
Usually because of receptor desensitization rather than worsening disease. Continuous exposure prevents the receptor from cycling, which reduces the effect of the same dose over time and can eventually amplify pain.
My last doctor tapered me quickly and it was awful. Is that normal?
It is common, and it is not good practice. An abrupt taper without an alternative in place predictably produces withdrawal and rebound pain. That experience does not mean tapering cannot work; it means that one was run without a bridge on the other side.
Key takeaways
- Opioid desensitization is a receptor biologic fact, which is why an opioid is a bridge and not a bridge you can live on.
- Abrupt or forced tapering is not the safe alternative to over-prescribing. It is a second way to harm the same patient.
- “First, do no harm” requires weighing both sides of a decision, not defaulting to inaction.
- A dose can come down safely when something else takes over the work it was doing.
Find the source of your pain — not just the signal
If you are on long-term opioids and the dose keeps climbing, or you have been told to taper with no plan for what happens next, that is a diagnostic problem before it is a medication problem. Request an appointment or call (314) 481-5000.
Related reading
- Why long-acting opioids can make pain worse
- Is your pain medication making your pain worse?
- Opioid bankruptcy: why the account runs dry from both ends
- Opioid tapering: medication is a bridge, not a destination
- Opioid stewardship: what pharmacists and referring physicians should know
Dr. Gurpreet Singh Padda, MD, MBA, MHP
